Savings Image


With Prestium Pharma's Prescription Savings Program, your patients can save up to $45 off out-of-pocket costs each time their pharmacist fills or refills the prescription. Ask for a supply of Prescription Savings Cards to provide your patients with their script.

The cards are valid at participating pharmacies for one use per medicine per month. Not valid for patients under Medicaid, Medicare (including Medicare Part D), or similar state or federal programs. The card is not valid for residents of Massachusetts unless the patient is paying the full cost of the prescription.

How the Prestium Pharma Combo Savings Card Works for Your Patients:


  • Pay the initial $15, you could recieve up to $45 off your co-pay or out-of-pocket expenses.

  • You may pay more than $15 if your co-pay exceeds $60; if your insurance does not cover Denavir, Elimite, Evoclin, Extina, Luxiq, Olux, Olux-E or Vusion; or if you are a chase payer.

  • Go to for more information.

  • For assistance with the Prestium Pharma Combo Savings Card, contact 1-855-820-3232.

  • After each transaction, keep this card for up to 12 total uses.



Full Prescribing Information

  • OLUX-E® (clobetasol propionate) Foam, 0.05% has been shown to reversibly suppress the hypothalamic-pituitary-adrenal (HPA) axis with the potential for clinical glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of the topical corticosteroid. Evaluate patients periodically for evidence of HPA axis suppression.

  • Cushing's Syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Use of OLUX-E Foam for longer than 2 weeks may suppress the immune system.

  • Factors that predispose a patient using a topical corticosteroid to increased total systemic corticosteroid exposure and HPA axis suppression include the use of more potent steroids, use of more than one corticosteroid-containing product at the same time, use over large surface areas, use over prolonged periods, use under occlusion, use on an altered skin barrier, and use in patients with liver failure.

  • The pooled incidence of local adverse reactions in trials for atopic dermatitis and psoriasis with OLUX-E Foam was 1.9% for application site atrophy and 1.6% for application site reaction.

  • OLUX-E Foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

  • Caution should be exercised when OLUX-E Foam is administered to a nursing woman. If used during lactation, OLUX-E Foam should not be applied to the chest to avoid accidental ingestion by the infant.

  • The propellant in this foam is flammable; patients should avoid fire, flame, and/or smoking during and immediately following application.

OLUX-E Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients aged 12 years and older.